1-20 of 266
Ian W. Flinn
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

ZUMA-8: A Phase 1 Study of Brexucabtagene Autoleucel in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia

Available to Purchase
Clinical Trials & Observations
Matthew S. Davids, Saad S. Kenderian, Ian W. Flinn, Brian T. Hill, Michael B Maris, Paolo Ghia, Michael T. Byrne, Nancy L. Bartlett, John Pagel, Yan Zheng, Justyna Kanska, Wangshu Zhang, Enrique Granados, Javier Pinilla-Ibarz
Journal: Blood
Blood blood.2024027460.
https://doi.org/10.1182/blood.2024027460
Published: 2025
Includes: Supplemental data
Journal Articles

Acalabrutinib-Obinutuzumab Improves Survival vs Chemoimmunotherapy in treatment-naive CLL in the 6-year Follow-up of ELEVATE-TN

Open Access
Clinical Trials & Observations
Jeff P. Sharman, Miklos Egyed, Wojciech Jurczak, Alan P Skarbnik, Krish Patel, Ian W. Flinn, Manali Kamdar, Talha Munir, Renata Walewska, Marie Hughes, Laura Maria Fogliato, Yair Herishanu, Versha Banerji, George A. Follows, Patricia A Walker, Paolo Ghia, Ann MH Janssens, John C Byrd, Emmanuelle France Ferrant, Alessandra Ferrajoli, William G. Wierda, Catherine Wangui Wachira, Batul T. Suterwala, Paulo A Palhares de Miranda, Veerendra Munugalavadla, Chuan-Chuan Wun, Jennifer A. Woyach
Journal: Blood
Blood blood.2024024476.
https://doi.org/10.1182/blood.2024024476
Published: 2025
Includes: Supplemental data
Journal Articles

Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine for advanced-stage classical Hodgkin lymphoma

Free
CME Clinical Trials & Observations
Hun Ju Lee, Rod Ramchandren, Judah Friedman, Jason Melear, Ian W. Flinn, John M. Burke, Yuliya Linhares, Paul Gonzales, Matthew Peterson, Mihir Raval, Rangaswamy Chintapatla, Tatyana A. Feldman, Habte Yimer, Miguel Islas-Ohlmayer, Ameet Patel, Leland Metheny, Asad Dean, Vishal Rana, Mitul D. Gandhi, John Renshaw, Linda Ho, Michelle A. Fanale, Wenchuan Guo, Christopher A. Yasenchak
Journal: Blood
Blood (2025) 145 (3): 290–299.
https://doi.org/10.1182/blood.2024024681
Published: 2025
Includes: Supplemental data
Journal Articles

Mosunetuzumab Monotherapy Demonstrates Encouraging Activity and a Manageable Safety Profile in Patients with Heavily Pre-Treated Relapsed or Refractory Mantle Cell Lymphoma

Free
L. Elizabeth Budde, Matthew Matasar, Laurie H. Sehn, Sarit E. Assouline, John Kuruvilla, Ian W. Flinn, Sung-Soo Yoon, Francesc Bosch, Daniel Greenwald, Norma C. Gutierrez, Dimitrios Tzachanis, Paula Marlton, Delaney McGuirt, Shen Yin, Michael C. Wei, Antonia Kwan, Samuel Tracy, Elicia Penuel, Nancy L. Bartlett
Journal: Blood
Blood (2024) 144 (Supplement 1): 1646.
https://doi.org/10.1182/blood-2024-197902
Published: 2024
Journal Articles

Fixed-Duration Subcutaneous Mosunetuzumab Is Active and Has a Manageable Safety Profile in Patients with Previously Untreated, Low-Tumor Burden Follicular Lymphoma: Updated Results from the Phase II Morningsun Study

Free
John M. Burke, Ian W. Flinn, L. Elizabeth Budde, Aung M. Tun, Steven Liu, Juliana M.L. Biondo, Prachi Jani, Mei Wu, Yong Mun, Vivek S. Chopra, Jessica M. Grindheim, Dana Farinella, Jose C. Villasboas Bisneto
Journal: Blood
Blood (2024) 144 (Supplement 1): 3008.
https://doi.org/10.1182/blood-2024-194604
Published: 2024
Journal Articles

Deep and Sustained Responses in Patients with CLL Treated with Zanubrutinib or Zanubrutinib + Obinutuzumab in Phase 1/2 AU-003 and Phase 1b GA-101 Studies: A Report from the Zanubrutinib Extension Study

Free
Constantine S. Tam, Stephen S. Opat, Eileen Grace Merriman, Jan A. Burger, Emma Verner, Paula Marlton, David Gottlieb, Ian W. Flinn, Sumit Madan, Matthew Ku, Radha Prathikanti, Heather Allewelt, Tian Tian, Remus Vezan, Gavin Cull
Journal: Blood
Blood (2024) 144 (Supplement 1): 3255.
https://doi.org/10.1182/blood-2024-200363
Published: 2024
Journal Articles

A Single-Arm, Phase II Study of Acalabrutinib As Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Mantle Cell Lymphoma

Free
Michael T. Tees, Nakhle S Saba, Suman Kambhampati, Ian W. Flinn
Journal: Blood
Blood (2024) 144 (Supplement 1): 6321.
https://doi.org/10.1182/blood-2024-193140
Published: 2024
Journal Articles

Zanubrutinib is Well Tolerated and Effective in Acalabrutinib-Intolerant Patients with B-cell Malignancies

Free
Mazyar Shadman, Ian W. Flinn, Moshe Y. Levy, Benjamin B. Freeman, Ben Zhang, John M. Burke, Jennifer L. Cultrera, Habte A. Yimer, Edwin C. Kingsley, Charles M. Farber, James D'Olimpio, Hui Yao, Adam Idoine, Qi An, Jeff P. Sharman
Journal: Blood
Blood (2024) 144 (Supplement 1): 4632.
https://doi.org/10.1182/blood-2024-198250
Published: 2024
Journal Articles

Rapcabtagene Autoleucel (YTB323) in Patients (Pts) with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Phase II Trial Clinical Update

Free
Peter A. Riedell, Mi Kwon, Ian W. Flinn, Michael J. Dickinson, Carlos Solano, Ulrich Jaeger, Javier Briones, Koji Kato, Shaun Fleming, Emmanuel Bachy, Alessandro Rambaldi, Leyla O. Shune, Nirav N. Shah, Didier Blaise, Matthew J. Frigault, Aravind Ramakrishnan, Anne Yang, David Pearson, Aiesha Zia, Eduardo Segura, Aisha Masood, Pere Barba
Journal: Blood
Blood (2024) 144 (Supplement 1): 67.
https://doi.org/10.1182/blood-2024-204264
Published: 2024
Journal Articles

Five-Year Outcomes of Patients (Pts) with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Treated with Brexucabtagene Autoleucel (Brexu-cel) in ZUMA-2 Cohorts 1 and 2

Free
Michael Wang, Andre Goy, Javier Munoz, Frederick L. Locke, Caron A. Jacobson, Brian T. Hill, John Timmerman, Ian W. Flinn, David B. Miklos, John M. Pagel, Marie José Kersten, Edouard Forcade, Max S. Topp, Roch Houot, Amer Beitinjaneh, Dan Zheng, Mengru Chang, Rhine Shen, Wangshu Zhang, Rita Damico Khalid, Ioana Kloos, Patrick M. Reagan
Journal: Blood
Blood (2024) 144 (Supplement 1): 4388.
https://doi.org/10.1182/blood-2024-198018
Published: 2024
Journal Articles

A Randomized Phase 2 Study Incorporating Nivolumab and Brentuximab Vedotin into Radiation-Free Treatment of Early Stage Classic Hodgkin Lymphoma

Free
Ann S. LaCasce, Deepa Jagadeesh, Hun Ju Lee, Lu Chen, David A. Bond, Matthew Weinstock, Matthew Mei, Tatyana Feldman, Allison M. Winter, Jeffrey A. Barnes, Amitkumar N. Mehta, Gaurav Goyal, Sairah Ahmed, Lisa Giulino Roth, Azra Borogovac, Kristie A. Blum, Jane N Winter, Mehdi Hamadani, Sonali M. Smith, Philippe Armand, Ian W. Flinn, Jeremy S. Abramson, Alex F. Herrera
Journal: Blood
Blood (2024) 144 (Supplement 1): 459.
https://doi.org/10.1182/blood-2024-204113
Published: 2024
Journal Articles

Genomic Landscape of Ibrutinib- and/or Acalabrutinib-intolerant Patients with B-cell Malignancies Treated with Zanubrutinib in a Phase 2 Study

Free
Linlin Xu, Mazyar Shadman, Ian W. Flinn, Moshe Levy, Ryan Porter, John M. Burke, Syed F. Zafar, Jennifer L. Cultrera, Jamal Misleh, Edwin C. Kingsley, Habte A. Yimer, Benjamin B. Freeman, Arvind Chaudhry, Praveen K. Tumula, Mitul Gandhi, Rocco J. Crescenzo, Kunthel By, Aileen Cleary Cohen, Adam Idoine, Sudhir Manda, Jeff P. Sharman
Journal: Blood
Blood (2023) 142 (Supplement 1): 6510.
https://doi.org/10.1182/blood-2023-180161
Published: 2023
Journal Articles

Response to Mosunetuzumab in Patients with B-Cell Lymphomas Relapsed or Refractory after CAR-T Cell Therapy Is Associated with Changes in Lymphocyte Counts

Free
Elise A. Chong, Elicia Penuel, Nancy L. Bartlett, Francesc Bosch, L. Elizabeth Budde, Keith Fay, Ian W. Flinn, Andre Goy, Anita Kumar, Rachel Lundberg, Ellen B. Napier, Loretta J. Nastoupil, Mazyar Shadman, Michael C. Wei, Mei Wu, Shen Yin, Emeline R. Chong, Stephen J. Schuster
Journal: Blood
Blood (2023) 142 (Supplement 1): 1752.
https://doi.org/10.1182/blood-2023-190201
Published: 2023
Journal Articles

Subcutaneous Mosunetuzumab Is Active and Has a Manageable Safety Profile in Patients with Previously Untreated, Low-Tumor Burden Follicular Lymphoma: Initial Results from the Phase II Morningsun Study

Free
Ian W. Flinn, L. Elizabeth Budde, Aung M. Tun, John M. Burke, Bertrand Anz, Shachar Peles, Jeff P. Sharman, Praveen K. Tumula, Juliana M. L. Biondo, Prachi Jani, Mei Wu, Tony Lin, Neha Parmar, Yong Mun, Nai-Shun Yao, Steven Liu
Journal: Blood
Blood (2023) 142 (Supplement 1): 3029.
https://doi.org/10.1182/blood-2023-177917
Published: 2023
Journal Articles

Outcomes of Patients with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Treated with Brexucabtagene Autoleucel (Brexu-cel) in ZUMA-2 and ZUMA-18, an Expanded Access Study

Free
Andre Goy, Caron A. Jacobson, Ian W. Flinn, Brian T. Hill, Wen-Kai Weng, Luke Mountjoy, Oluwole Olalekan, Dan Zheng, Ana Nunes, Wangshu Zhang, Rhine R. Shen, Ioana Kloos, Michael L. Wang
Journal: Blood
Blood (2023) 142 (Supplement 1): 106.
https://doi.org/10.1182/blood-2023-174273
Published: 2023
Journal Articles

Zanubrutinib in Acalabrutinib-Intolerant Patients (Pts) with B-Cell Malignancies

Free
Mazyar Shadman, Ian W. Flinn, Edwin C. Kingsley, Benjamin B. Freeman, Moshe Levy, Charles M. Farber, James D'Olimpio, Jennifer L. Cultrera, Ben Zhang, Rocco J. Crescenzo, Adam Idoine, Xiaoping Zhang, Kunthel By, Jeff P. Sharman
Journal: Blood
Blood (2023) 142 (Supplement 1): 3279.
https://doi.org/10.1182/blood-2023-174096
Published: 2023
Journal Articles

Bendamustine Versus Fludarabine and Cyclophosphamide for Lymphodepletion Prior to CAR-T Therapy

Free
Uttam K Rao, Betsy Blunk, Carlos Bachier, Vikas Bhushan, Jose Carlos Cruz, Mohammed Elayan, Ian W. Flinn, Tara Gregory, Charles F. LeMaistre, Navneet Majhail, Shahbaz A. Malik, Casey Martin, Michael B. Maris, John Mathews, Luke Mountjoy, Jeremy M. Pantin, Aravind Ramakrishnan, Paul Shaughnessy, Michael T. Tees, Estil A. Vance, Behyar Zoghi, MD, PhD, FACP, Minoo Battiwalla
Journal: Blood
Blood (2023) 142 (Supplement 1): 3504.
https://doi.org/10.1182/blood-2023-190388
Published: 2023
Journal Articles

Improved Overall Survival with Axicabtagene Ciloleucel Vs Standard of Care in Second-Line Large B-Cell Lymphoma Among the Elderly: A Subgroup Analysis of ZUMA-7

Free
Marie José Kersten, Umar Farooq, Aaron P. Rapoport, Frederick L. Locke, Lori A. Leslie, Armin Ghobadi, David B. Miklos, Caron A. Jacobson, Javier L. Munoz, Patrick B Johnston, Samantha M. Jaglowski, Ian W. Flinn, Tom van Meerten, Miguel-Angel Perales, Peter Vandenberghe, Peter A. Riedell, Kathleen Dorritie, David Szwajcer, Dimitrios Tzachanis, Saran Vardhanabhuti, Linqiu Du, Simone Filosto, Shilpa A. Shahani, Christina To, Jason Westin
Journal: Blood
Blood (2023) 142 (Supplement 1): 1761.
https://doi.org/10.1182/blood-2023-173873
Published: 2023
Journal Articles

A First-in-Human Phase 1 Trial of NX-2127, a First-in-Class Bruton's Tyrosine Kinase (BTK) Dual-Targeted Protein Degrader with Immunomodulatory Activity, in Patients with Relapsed/Refractory B Cell Malignancies

Free
Alexey Danilov, Michael T. Tees, Krish Patel, William G. Wierda, Manish Patel, Ian W. Flinn, Tahir Latif, Weiyun Ai, Meghan C. Thompson, Michael L. Wang, Clare Sun, Deborah M. Stephens, Michael J Thirman, Melissa Gessner, Johannes Wolff, Amanda Schwab, May Tan, Daniel Chan, Erin Meredith, Adrian Wiestner
Journal: Blood
Blood (2023) 142 (Supplement 1): 4463.
https://doi.org/10.1182/blood-2023-179872
Published: 2023
Journal Articles

Patient-Reported Outcomes (PROs) Among Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Receiving Pirtobrutinib: Analysis from the BRUIN Phase 1/2 Study

Free
Catherine C. Coombs, Jennifer A. Woyach, Jennifer R. Brown, Paolo Ghia, Lindsey E. Roeker, Krish Patel, Toby A. Eyre, Constantine S. Tam, John F. Seymour, Nirav N. Shah, Ian W. Flinn, Chan Y. Cheah, Shuo Ma, Joanna M. Rhodes, Koji Izutsu, Wojciech Jurczak, William G. Wierda, Angely Loubert, Nalin Payakachat, Lisa M. Hess, Paolo Abada, Nicole Lamanna
Journal: Blood
Blood (2023) 142 (Supplement 1): 6535.
https://doi.org/10.1182/blood-2023-186145
Published: 2023